Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related ARWR
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520
Related FMI
Foundation Medicine Reports Identified Patients Likely to Respond to Certain MET Inhibitor Target Therapies, Durable Responses Shown in Presentation at ASCO
Leerink Is Changing Targets At These 7 Biotechs
After Hours Gainers / Losers (Seeking Alpha)

Analysts at Piper Jaffray initiated coverage on shares of Arrowhead Research (NASDAQ: ARWR) with an “overweight” rating. The target price for Arrowhead Research is set to $12. Arrowhead Research's shares closed at $7.87 on Friday.

Analysts at Goldman Sachs initiated coverage on shares of Foundation Medicine (NASDAQ: FMI) with a “neutral” rating. The target price for Foundation Medicine is set to $33. Foundation Medicine's stock closed at $33.99 on Friday.

JP Morgan initiated coverage on shares of Premier (NASDAQ: PINC) with an “overweight” rating. The target price for Premier is set to $36. Premier's shares closed at $31.66 on Friday.

Morgan Stanley initiated coverage on shares of Ophthotech (NASDAQ: OPHT) with an “overweight” rating. The target price for Ophthotech is set to $56. Ophthotech's shares closed at $29.25 on Friday.

Latest Ratings for ARWR

DateFirmActionFromTo
Apr 2015JefferiesDowngradesBuyHold
Jan 2015Deutsche BankDowngradesBuyHold
Oct 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ARWR + FMI)

Get Benzinga's Newsletters